Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — Merger or Acquisition (June 2025)
8 slides from Bristol-myers Squibb's merger presentation, Jun 2, 2025
Slide 1: A Transformative Global Partnership for BNT327 (PD-L1 x VEGF-A bispecific antibody)
A Transformative Global Partnership for BNT327 (PD-L1 x VEGF-A bispecific antibody) June 2, 2025
Slide 2: This Slide Presentation Includes Forward-Looking Statements
This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: expectations regarding the impact of the col
Slide 3: Forward Looking Statements and Non-GAAP Financial Information
Forward Looking Statements and Non-GAAP Financial Information This presentation contains “forward-looking statements” within the meaning of the Private management has evaluated the Company’s financial results both including and excluding the Securities Litigation Reform Act of 1995 regarding, among
Slide 4: BioNTech and Bristol Myers Squibb Enter Landmark Strategic Partnership to Advance BNT327 & Oncology Leadership
BioNTech and Bristol Myers Squibb Enter Landmark Strategic Partnership to Advance BNT327 & Oncology Leadership Anti-VEGF-A Maximizing Potential of Next-generation Immunomodulator BNT327 with Global Co-development and Co-commercialization Partnership • Bispecific antibody targeting PD-L1 and VEGF-A •
Slide 5: BNT327: Potential to Establish a New Standard of Care Across Multiple Tumor Types
BNT327: Potential to Establish a New Standard of Care Across Multiple Tumor Types >1,000 Clinical activity across indications patients enrolled 10+ Including SCLC, NSCLC, TNBC, RCC, MPM and others indications studied1 20+ Including studies in 1L or 2L+ with SoC & novel combinations clinical trials o
Slide 6: Harnessing Complementary Expertise to Maximize BNT327 Potential
Harnessing Complementary Expertise to Maximize BNT327 Potential Leadership position in the Patient-centric scientific Pioneer in shaping IO field, focused on PD-(L)1xVEGF space and personalized further bolstering leadership position in mRNA cancer immunotherapies excellence oncology Unique pipeline
Slide 7: Deal Terms
Deal Terms1 Cost share of joint trials 50:50 (subject to certain exceptions) Co-Development BioNTech and BMS retain full rights to exploit any of its proprietary assets in combination with BNT327 Co-commercialization in all global markets: Co- Commercialization BioNTech to book sales in the U.S. and
Slide 8: Abbreviation Directory
Abbreviation Directory nL nth line VEGF-A Vascular endothelial growth factor A ADC Antibody-drug conjugate VHH Heavy chain variable BMS Bristol Myers Squibb SoC Standard of care BNT BioNTech TNBC Triple-negative breast cancer BTC Biliary tract cancer UK United Kingdom CTx Chemotherapy US United Stat
Bristol Myers Squibb — Merger or Acquisition (June 2025) on 6ix